Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 0.88%.

  • Coherus Oncology's Return on Capital Employed fell 1200.0% to 0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88%, marking a year-over-year decrease of 1200.0%. This contributed to the annual value of 0.44% for FY2024, which is 4700.0% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Return on Capital Employed is 0.88%, which was down 1200.0% from 0.67% recorded in Q2 2025.
  • Coherus Oncology's Return on Capital Employed's 5-year high stood at 0.1% during Q1 2021, with a 5-year trough of 1.28% in Q1 2024.
  • For the 5-year period, Coherus Oncology's Return on Capital Employed averaged around 0.64%, with its median value being 0.65% (2022).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -7800bps in 2021, then skyrocketed by 7100bps in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Return on Capital Employed stood at 0.48% in 2021, then crashed by -41bps to 0.68% in 2022, then dropped by -9bps to 0.74% in 2023, then rose by 22bps to 0.58% in 2024, then crashed by -52bps to 0.88% in 2025.
  • Its Return on Capital Employed stands at 0.88% for Q3 2025, versus 0.67% for Q2 2025 and 0.58% for Q1 2025.